How often is Reslizumab (Cinqair) administered?

Reslizumab (Cinqair) is administered every 4 weeks, making this option correct. This medication is specifically used as a treatment for individuals with severe asthma that is associated with elevated levels of eosinophils, which are a type of white blood cell involved in allergic reactions and inflammation. The dosing schedule of every 4 weeks is designed to maintain therapeutic levels in the body while minimizing the frequency of injections for patients, thus improving adherence and convenience.

In terms of the other choices, the infrequent nature of the required administration aligns with the pharmacologic properties of Reslizumab, which allows for longer intervals between doses compared to medications that might need to be taken weekly or daily. The extended dosing schedule is effective for the management of chronic conditions like asthma, where consistent but not continuous management is necessary for optimal results.